Xencor, Inc. (XNCR) Holdings Boosted by Legal & General Group Plc

Legal & General Group Plc raised its position in Xencor, Inc. (NASDAQ:XNCR) by 4.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,978 shares of the biopharmaceutical company’s stock after purchasing an additional 385 shares during the quarter. Legal & General Group Plc’s holdings in Xencor were worth $189,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Xencor by 5.2% in the 1st quarter. Vanguard Group Inc. now owns 1,611,115 shares of the biopharmaceutical company’s stock valued at $38,537,000 after purchasing an additional 79,445 shares during the last quarter. Redmile Group LLC boosted its holdings in Xencor by 59.9% in the 1st quarter. Redmile Group LLC now owns 1,592,526 shares of the biopharmaceutical company’s stock valued at $38,093,000 after purchasing an additional 596,426 shares during the last quarter. State Street Corp boosted its holdings in Xencor by 17.5% in the 1st quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after purchasing an additional 148,136 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Xencor by 8.0% in the 1st quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock valued at $8,783,000 after purchasing an additional 27,099 shares during the last quarter. Finally, Teachers Advisors LLC boosted its holdings in Xencor by 1.2% in the 1st quarter. Teachers Advisors LLC now owns 323,782 shares of the biopharmaceutical company’s stock valued at $7,745,000 after purchasing an additional 3,868 shares during the last quarter. Institutional investors own 76.92% of the company’s stock.

Xencor (NASDAQ:XNCR) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The business had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million.

In related news, major shareholder John S. Stafford III bought 41,016 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were acquired at an average cost of $19.69 per share, with a total value of $807,605.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder John S. Stafford III bought 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was bought at an average cost of $20.96 per share, for a total transaction of $524,000.00. The disclosure for this purchase can be found here. Insiders purchased 215,551 shares of company stock worth $4,386,916 over the last three months. Corporate insiders own 4.03% of the company’s stock.

Several equities analysts have weighed in on the stock. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 target price on shares of Xencor in a report on Tuesday, August 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $29.00 target price on shares of Xencor in a report on Friday, June 16th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. Xencor currently has an average rating of “Hold” and an average price target of $28.00.

COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (XNCR) Holdings Boosted by Legal & General Group Plc” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.themarketsdaily.com/2017/10/13/xencor-inc-xncr-holdings-boosted-by-legal-general-group-plc.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply